Fredag 20 Juni | 05:35:35 Europe / Stockholm

Kalender

Est. tid*
2025-08-29 07:00 Kvartalsrapport 2025-Q2
2025-04-25 - X-dag ordinarie utdelning TRMED 0.00 NOK
2025-04-24 - Årsstämma
2025-02-26 - Bokslutskommuniké 2024
2025-01-06 - Extra Bolagsstämma 2025
2024-08-30 - Kvartalsrapport 2024-Q2
2024-04-12 - X-dag ordinarie utdelning TRMED 0.00 NOK
2024-04-11 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-08-31 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning TRMED 0.00 NOK
2023-04-26 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-08-31 - Kvartalsrapport 2022-Q2
2022-04-29 - X-dag ordinarie utdelning TRMED 0.00 NOK
2022-04-28 - Årsstämma
2022-03-01 - Bokslutskommuniké 2021
2021-11-18 - 15-10 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-26 - Kvartalsrapport 2021-Q1
2021-04-28 - Årsstämma
2021-04-16 - X-dag ordinarie utdelning TRMED 0.00 NOK
2021-03-22 - Extra Bolagsstämma 2021
2021-02-18 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-10-21 - Extra Bolagsstämma 2020
2020-08-27 - Kvartalsrapport 2020-Q2
2020-06-11 - X-dag ordinarie utdelning TRMED 0.00 NOK
2020-06-10 - Årsstämma
2020-05-26 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-19 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-23 - Kvartalsrapport 2019-Q1
2019-04-26 - X-dag ordinarie utdelning TRMED 0.00 NOK
2019-04-25 - Årsstämma
2019-02-18 - Extra Bolagsstämma 2019
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-31 - X-dag ordinarie utdelning TRMED 0.00 NOK
2018-05-30 - Årsstämma
2018-05-30 - Kvartalsrapport 2018-Q1
2018-02-27 - Bokslutskommuniké 2017
2017-12-20 - Extra Bolagsstämma 2017
2017-11-22 - Kvartalsrapport 2017-Q3
2017-08-23 - Kvartalsrapport 2017-Q2
2017-05-26 - X-dag ordinarie utdelning TRMED 0.00 NOK
2017-05-24 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-02-28 - Bokslutskommuniké 2016
2016-11-23 - Kvartalsrapport 2016-Q3
2016-10-12 - Extra Bolagsstämma 2016
2016-08-24 - Kvartalsrapport 2016-Q2
2016-05-31 - Kapitalmarknadsdag 2016
2016-05-20 - X-dag ordinarie utdelning TRMED 0.00 NOK
2016-05-19 - Årsstämma
2016-05-19 - Kvartalsrapport 2016-Q1
2016-02-26 - Bokslutskommuniké 2015
2015-11-17 - Kapitalmarknadsdag 2015
2015-10-21 - Kvartalsrapport 2015-Q3
2015-08-26 - Kvartalsrapport 2015-Q2
2015-05-27 - Kvartalsrapport 2015-Q1
2015-03-09 - Årsstämma
2014-11-12 - Extra Bolagsstämma 2014

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriLäkemedel & Handel
Thor Medical är ett läkemedelsbolag. Bolaget specialiserar sig inom utveckling av antikroppsläkemedel för behandling utav hematologisk cancer. Störst specialisering återfinns inom precisionsterapi som används i den kliniska fasen. Övriga sjukdomar som behandlas är non-hodgkins lymfom (NHL). Bolaget grundades under 2009 och har sitt huvudkontor i Oslo, Norge.
2025-06-18 23:46:57
18.6.2025 23:46:55 CEST | Thor Medical ASA | Additional regulated information
required to be disclosed under the laws of a member state

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS,
ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA) (THE
"UNITED STATES"), AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION
OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH
THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

Oslo, 18 June 2025: Reference is made to the stock exchange announcement by Thor
Medical ASA (the "Company") on 18 June 2025 regarding the completion of a
private placement of new shares in the Company raising NOK 75 million in gross
proceeds (the "Private Placement") and a separate retail offering in Norway,
Denmark, Finland and Sweden of new shares in the Company, raising gross proceeds
of up to the NOK equivalent of EUR 1 million through the PrimaryBid platform
(the "PrimaryBid Offering") and that the Company is considering conducting a
subsequent share offering (the "Subsequent Offering") with non-tradeable
subscription rights of up to 4,000,000 new shares in the Company, which, subject
to applicable securities law, will be directed towards existing shareholders in
the Company as of 18 June 2025 (as registered in Euronext Securities Oslo on 20
June 2025), who (i) were not included in the pre-sounding phase of the Private
Placement, (ii) were not allocated Offer Shares in the Private Placement, and
(iii) are not resident in a jurisdiction where such offering would be unlawful,
or would (in jurisdictions other than Norway) require any prospectus filing,
registration or similar action.

The following key information is provided with respect to the Subsequent
Offering:

Date for announcement of terms: 18 June 2025

Last day including right to receive subscription rights: 18 June 2025

First day excluding right to receive subscription rights: 19 June 2025

Record date: 20 June 2025

Maximum number of new shares: 4,000,000

Subscription price: NOK 2.50

Shall the subscription rights be listed: No

The Subsequent Offering will be subject to (i) the prevailing market price of
the Company's shares, (ii) relevant corporate resolutions being passed by the
Company, and (iii) registration of a national prospectus with the Norwegian
Register of Business Enterprises.

The formal resolution (including the final number of new shares to be offered)
related to any Subsequent Offering will be made by the board of directors in the
Company.

This information is published in accordance with the requirements of the
Continuing Obligations for issuers listed on Euronext Oslo Børs.



Contacts

Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.com

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.no - http://www.thormedical.no



Important Notices

This announcement is not and does not form a part of any offer to sell, or a
solicitation of an offer to purchase, any securities of the Company. Copies of
this announcement are not being made and may not be distributed or sent into any
jurisdiction in which such distribution would be unlawful or would require
registration or other measures.

The securities referred to in this announcement have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the "Securities
Act"), and accordingly may not be offered or sold in the United States absent
registration or an applicable exemption from the registration requirements of
the Securities Act and in accordance with applicable U.S. state securities laws.
The Company does not intend to register any part of the offering in the United
States or to conduct a public offering of securities in the United States. Any
sale in the United States of the securities mentioned in this announcement will
be made solely to "qualified institutional buyers" as defined in Rule 144A under
the Securities Act.

This announcement is an advertisement and is not a prospectus for the purposes
of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14
June 2017 (the "EU Prospectus Regulation") (together with any applicable
implementing measures in any Member State). All of the securities referred to in
this announcement has been offered by means of a set of subscription materials
provided to potential investors, except for the potential Subsequent Offering
which will be made on the basis of a listing and offering prospectus. Investors
should not subscribe for any securities referred to in this announcement except
on the basis of information contained in the aforementioned subscription
materials or for the Subsequent Offering, the prospectus.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation, i.e., only to investors who can receive the offer without
an approved prospectus in such EEA Member State. The "Prospectus Regulation"
means Regulation (EU) 2017/1129, as amended (together with any applicable
implementing measures) in any Member State.

This communication is only being distributed to and is only directed at persons
in the United Kingdom that are (i) investment professionals falling within
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities,
and other persons to whom this announcement may lawfully be communicated,
falling within Article 49(2)(a) to (d) of the Order (all such persons together
being referred to as "relevant persons"). This communication must not be acted
on or relied on by persons who are not relevant persons. Any investment or
investment activity to which this communication relates is available only for
relevant persons and will be engaged in only with relevant persons. Persons
distributing this communication must satisfy themselves that it is lawful to do
so.

The issue, subscription or purchase of shares or other financial instruments in
the Company is subject to specific legal or regulatory restrictions in certain
jurisdictions. Neither the Company nor the Managers assume any responsibility in
the event there is a violation by any person of such restrictions. The
distribution of this release may in certain jurisdictions be restricted by law.
Persons into whose possession this release comes should inform themselves about
and observe any such restrictions. Any failure to comply with these restrictions
may constitute a violation of the securities laws of any such jurisdiction.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as "believe", "expect", "anticipate",
"strategy", "intends", "estimate", "will", "may", "continue", "should" and
similar expressions. Any forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Although the Company believe that these assumptions were reasonable
when made, these assumptions are inherently subject to significant known and
unknown risks, uncertainties, contingencies and other important factors which
are difficult or impossible to predict, and are beyond their control. Actual
events may differ significantly from any anticipated development due to a number
of factors, including without limitation, changes in public sector investment
levels, changes in the general economic, political and market conditions in the
markets in which the Company operates, the Company's ability to attract, retain
and motivate qualified personnel, changes in the Company's ability to engage in
commercially acceptable acquisitions and strategic investments, and changes in
laws and regulation and the potential impact of legal proceedings and actions.
Such risks, uncertainties, contingencies and other important factors could cause
actual events to differ materially from the expectations expressed or implied in
this release by such forward-looking statements. The Company does not make any
guarantee that the assumptions underlying the forward-looking statements in this
announcement are free from errors nor does it accept any responsibility for the
future accuracy of the opinions expressed in this announcement or any obligation
to update or revise the statements in this announcement to reflect subsequent
events. You should not place undue reliance on the forward-looking statements in
this announcement.

The information, opinions and forward-looking statements contained in this
announcement speak only as at its date and are subject to change without notice.
The Company does not undertake any obligation to review, update, confirm, or to
release publicly any revisions to any forward-looking statements to reflect
events that occur or circumstances that arise in relation to the content of this
announcement.

Neither the Managers nor any of its affiliates makes any representation as to
the accuracy or completeness of this announcement and none of them accepts any
responsibility or liability for the contents of this announcement or any matters
referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. Neither the
Managers nor any of its affiliates accepts any liability arising from the use of
this announcement.

The distribution of this announcement and other information may be restricted by
law in certain jurisdictions. Persons into whose possession this announcement or
such other information should come are required to inform themselves about and
to observe any such restrictions.



ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18570380/6228/Download%20announce
ment%20as%20PDF.pdf